A rare, transmissible tumor has brought the iconic Tasmanian devil to the brink of extinction, but new research by scientists at Washington State University and the Fred Hutchinson Cancer Research Center in Seattle indicates hope for the animals’ survival and possibly new treatment for human cancers.
The study, published in Genetics on Aug. 1, found a single genetic mutation that leads to reduced growth of a transmissible cancer in Tasmanian devils in the wild.
![Andrew Storfer.](https://wpcdn.web.wsu.edu/wp-cas/uploads/sites/648/2018/11/storfer_andrewl.jpg)
“This gene is implicated in human prostate and colon cancers,” said Andrew Storfer, professor of biological sciences at WSU. “While the findings hold the most immediate promise to help save the world’s few remaining Tasmanian devils, these results could also someday translate to human health.”
The research team, led by Storfer and Mark Margres, now a postdoctoral fellow at Harvard University, studied the genomes of cases of devil facial tumor disease, or DFTD, that regressed spontaneously — that is, the cancer began disappearing on its own.